r/EOSE

This thread is for general discussion related to EOS Energy (EOSE) and the broader investment thesis. Use it for discussion that doesn't warrant a standalone post, including:

• Short-term price action and market commentary
• News, rumours, and analyst notes
• Questions about financials, valuation, or strategy

Subreddit rules still apply. Low-effort posts, hype, and misinformation may be removed. If you’re sharing claims or data, provide sources when possible.

For major news or in-depth analysis, feel free to submit a separate post.

On Aug 6 an SEC filing showed Cerberus — yes, the firm from the Steward Health Care hospital bankruptcy — exercising penny warrants for ~20 million more shares of Eos Energy ($EOSE), pushing its stake from ~32.6% toward ~38%, with a contract that lets it reach 49%.
>
> The mechanics are the interesting part. The 2023 "$315.5M strategic investment" was mostly 
**debt**
 (a $210.5M term loan + $105M revolver, starting at 15% interest, released only as Eos hit milestones Cerberus defines) — plus penny warrants worth up to half the company for basically nothing. Meanwhile a 
**$303.5M U.S. Dept. of Energy loan guarantee**
 backstops the factory. So public money de-risks it, Cerberus's loan sits senior if it fails, and the warrants capture the upside if it flies.
>
> I put the whole thing together from the filings — genuinely curious what people here think: is this a rescue, or a takeover dressed as one? Breakdown's in the comments if useful.

Not financial advice — factual framing to help you form your own view. Sourced to primary filings/8-Ks/press releases throughout.

The Control Structure (context for everything below)
Cerberus became Eos's senior secured lender in June 2024, in exchange for warrants and preferred stock that converted into a large equity stake with full-ratchet anti-dilution protection, plus board representation. That gave Cerberus a position across every layer of the capital structure from that point forward — debt, equity, and governance simultaneously.

2025: Real, Organic Growth
Through 2025, Eos's revenue climbed cleanly — roughly $10.5M (Q1) → $15.2M (Q2) → $30.5M (Q3) → $58.0M (Q4) — with zero disclosed related-party revenue anywhere in the numbers for the first half of the year. This was a genuine, accelerating, independently-verifiable growth story.

October 2025 — A New Thread Appears
Cerberus committed capital (~£159M) into a UK developer, Frontier Power Ltd. — the only UK commercial relationship Eos has ever disclosed anywhere (their April 2025 MOU explicitly says this "marks Eos' entrance into a new international market"). FY2025's 10-K shows UK revenue of $21.5M — 18.8% of the full-year total — appearing for the first time that same year.

Feb 2026 — Guidance Set
Eos issues $300–400M FY2026 revenue guidance, based on the 2025 trajectory above.

March 31, 2026 — Backlog Already Softening
Backlog falls from $701.5M (year-end 2025) to $644.6M — an 8% quarterly decline, disclosed later but presumably visible internally in real time.

May 13, 2026 — FPUSA Announced, Same Day as the Backlog Reveal
Q1 results (showing the backlog decline) and the formation of Frontier Power USA (FPUSA) — a new Cerberus-anchored JV — are announced simultaneously. Guidance is reaffirmed unchanged. Structure at announcement: Eos targeting $150M, Cerberus committing $100M.

June 30, 2026 — Hudson Bay Backstop, Before the Rights Window Even Opens
Hudson Bay commits $125M ($75M direct to Eos, $50M to FPUSA) — arranged before the rights offering (meant to fund Eos's own FPUSA contribution) had even opened for subscription.

Result: 25% Subscription
The rights offering raises only $37.7M of its $150M target when it closes.

The Q2 Revenue Concentration
Separately — and before FPUSA legally existed — a Cerberus affiliate directly financed a project that Eos recognized as $55.034M of Q2 revenue (80% of the entire quarter), per the 10-Q's own related-party disclosure. That project was folded into FPUSA once it formally closed on August 4, 2026 — 83 days after the initial announcement. Final ownership: Eos 36.0%, Cerberus 48.0%, Hudson Bay 16.0% (confirmed to the exact unit count in the 10-Q), well below the 49% originally targeted for Eos. A separate mechanism in the JV agreement lets Cerberus absorb up to 90% of Hudson Bay's units at $1.00/unit if Hudson Bay ever exercises its exchange right.

The Backlog Pattern Underneath the Headline
The company discloses that "this project and FPUSA" = 49% of the $807M Q2 backlog. Backing that out: non-FPUSA backlog fell from $644.6M (Q1) to roughly $411.6M (Q2) — a ~36% organic decline, masked by the related-party addition that kept the headline backlog growing 25%.

Guidance Trimmed
Aug 5, 2026: full-year guidance cut to $300–350M.

Now, for balance — Line 2's actual operational progress, because this is genuinely moving forward regardless of the above:

• Commercial production began mid-June 2026, on schedule.
• Company states Site Acceptance Testing and commissioning are complete across all sub-assembly operations, with full automation online.
• Cycle times reported running ~10% faster (battery line) and ~11% faster (bipolar line) than Line 1.
• Currently operating one partial production shift, with full production capacity targeted for Q4 2026.
• Separately, Turtle Creek/Line 1 was described by management on the earnings call as "performing at nameplate."

Line 2 hitting full capacity in Q4 is the mechanism that's supposed to both grow the revenue base and deliver the guided "positive adjusted gross margin exit run-rate" — so Q4 is arguably the single highest-stakes quarter in this whole story, independent of anything else above.

Where this leaves things: every step in the timeline above is individually disclosed and legal. What's contestable is whether the sequence and timing — reaffirming guidance the same day a backlog decline is revealed, pre-arranging a backstop before a subscription window even opens, recognizing related-party revenue before the JV that's supposed to house it legally exists — reflects coordinated design or a distressed company and its dominant lender making individually rational decisions that happen to compound this way. That's not something filings alone can settle; it's the exact question the pending securities litigation (Yung, Berger complaints) exists to test through discovery.

Genuinely curious how others here weigh the Line 2 execution progress against the backlog/revenue-composition pattern — feels like the next two quarters (especially Q4) will tell us more than anything backward-looking can.